Comparative Pharmacology
Head-to-head clinical analysis: LISINOPRIL versus UNIRETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LISINOPRIL versus UNIRETIC.
LISINOPRIL vs UNIRETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased plasma angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, decreased sodium and water retention, and lower blood pressure.
Uniretic is a combination of an angiotensin-converting enzyme (ACE) inhibitor (moexipril) and a thiazide diuretic (hydrochlorothiazide). Moexipril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing excretion of sodium and water.
Initial: 5-10 mg orally once daily. Maintenance: 10-40 mg orally once daily. Max: 80 mg/day.
1-2 tablets (each containing hydrochlorothiazide 25 mg and spironolactone 25 mg) orally once daily. Maximum dose: 4 tablets/day.
None Documented
None Documented
Clinical Note
moderateLisinopril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Etacrynic acid."
Clinical Note
moderateLisinopril + Bumetanide
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Bumetanide."
Clinical Note
moderateLisinopril + Benzydamine
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Benzydamine."
Clinical Note
moderateLisinopril + Estrone sulfate
Terminal half-life approximately 12 hours (range 11–13 hours); clinical context: once-daily dosing for hypertension and heart failure; accumulation occurs with renal impairment.
Terminal elimination half-life 13-17 hours; clinical context: supports once-daily dosing
Renal: 100% unchanged via glomerular filtration and tubular secretion; negligible biliary/fecal elimination.
Renal: 50-70% unchanged; biliary/fecal: 10-15% as metabolites
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor and Diuretic
"The serum concentration of Estrone sulfate can be decreased when it is combined with Lisinopril."